Nathan Sadeghi-Nejad has 15 years experience as a professional health-care investor, most recently as a sector head for Highside Capital. He has worked on the sell side (with independent research boutiques Sturza¿s Medical Research and Avalon Research) and the buyside (at Kilkenny Capital prior to Highside). Sadeghi-Nejad is a graduate of Columbia University and lives in New York. You can follow him on Twitter @natesadeghi.
TheStreet Contributor Nate Sadeghi debates whether to buy Celgene ahead of a European decision on expanding use of its multiple myeloma drug Revlimid.
Healthcare investor Nate Sadeghi says Pfizer's arthritis drug and Arena's obesity drug will be approved, while confidence in Onyx's cancer drug has increased.
Health care investor Nate Sadeghi says Pfizer is holding back bad news on its Alzheimer's drug, tells Human Genome to sell to Glaxo and likes Vertex and Gilead Sciences.
A closer look at Bristol-Myers Squibb's hepatitis C drug BMS-094 raises troubling questions.
Healthcare investor Nathan Sadeghi-Nejad grades the hepatitis C drug stocks following the closely watched EASL conference.
The closely followed EASL meeting has begun with release of key hepatitis C drug data from Gilead and Bristol-Myers Squibb
Too many question, not enough answers regarding Bristol-Myers Squibb's supposed interest in buying Amylin.
Gilead's market dominance in HIV is not in peril but the company faces legitimate questions about its ability to innovate.
Cholesterol-lowering PCSK9 Inhibitors are real drugs but won't meet aggressive sales forecasts
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.